Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide

Journal of Nuclear Medicine

Volumn 50, Issue 12, 2009, Pages 2082-2089

  Sosabowski, Jane K ^a   Matzow, Torkjel ^a   Foster, Julie M ^a   Finucane, Ciara ^a   Ellison, David ^a   Watson, Susan A ^b   Mather, Stephen J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Gastrin; Medullary thyroid cancer; Oncology; Peptide; Peptides; Radiopharmaceutical

Indexed keywords

APH070 IN 111; CHOLECYSTOKININ B RECEPTOR; GASTRIN DERIVATIVE; MGD5 IN 111; MONOMER; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; GASTRIN; SINGLE HETEROCYCLIC RINGS;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CHEMICAL STRUCTURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIMERIZATION; DRUG DISTRIBUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RAT; RECEPTOR BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; NEOPLASM; PROTEIN STABILITY; PROTEIN TRANSPORT; RADIOGRAPHY; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; FEMALE; GASTRINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 1-RING; ISOTOPE LABELING; MICE; NEOPLASMS; PROTEIN STABILITY; PROTEIN TRANSPORT; RATS; RECEPTOR, CHOLECYSTOKININ B; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 73349124522     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.064808     Document Type: Article

References (23)

1. Reubi JC, Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer. 1996;67:644-647.
2. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30:781-793.
3. Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997;57:1377-1386.
4. Teunissen JJ, Kwekkeboom DJ, de Jong M, Esser JP, Valkema R, Krenning EP. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol. 2005;19:595-616.
5. Behr TM, Behe MP. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med. 2002;32:97-109.
6. Behe M, Behr TM. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers. 2002;66:399-418.
7. Béhé M, Reubi J, Nock B, Mäcke H, Breeman WAP, Bernard HF. Evaluation of a DOTA-minigastrin derivate for therapy and diagnosis for CCK-2 receptor positive tumours [abstract]. Eur J Nucl Med Mol Imaging. 2005;32(suppl 1):S78.
8. Kwekkeboom DJ, Bakker WH, Kooij PP, et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med. 2000;27:1312-1317.
9. Fröberg AC, de Jong M, Nock BA, et al. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:1265-1272.
10. Mather SJ, McKenzie AJ, Sosabowski JK, Morris TM, Ellison D, Watson SA. Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med. 2007;48:615-622.
11. Kessler H, Schudok M, Haupt A, eds. Dimerization of Cyclic Hexapeptides: Strong Increase of Biological Activity. New York, NY: Walter de Gruyter; 1989.
12. 3 targeted radiotracers for tumor imaging. Mol Pharm. 2006;3:472-487.
13. Mezo G, Czajlik A, Manea M, et al. Structure, enzymatic stability and antitumor activity of sea lamprey GnRH-III and its dimer derivatives. Peptides. 2007;28:806-820.
14. 111In-labelled minigastrin dimer [abstract]. Q J Nucl Med Mol Imaging. 2008;52(suppl 1):13.
15. Dijkraaf I, Wester HJ. Peptides, multimers and polymers. Handb Exp Pharmacol. 2008(185 Pt 2):61-92.
16. 3 integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging. 2007;34:267-273.
17. Harris TD, Cheesman E, Harris AR, et al. Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging agents. Bioconjug Chem. 2007;18:1266-1279.
18. Janssen M, Oyen WJ, Massuger LF, et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm. 2002;17:641-646.
19. 18F-labeled RGD and octreotide analogs. J Nucl Med. 2004;45:892-902.
20. Bapst JP, Froidevaux S, Calame M, Tanner H, Eberle AN. Dimeric DOTA-α-melanocyte-stimulating hormone analogs: synthesis and in vivo characteristics of radiopeptides with high in vitro activity. J Recept Signal Transduct Res. 2007;27:383-409.
21. Hultsch C, Pawelke B, Bergmann R, Wuest F. Synthesis and evaluation of novel multimeric neurotensin(8-13) analogs. Bioorg Med Chem. 2006;14:5913-5920.
22. Abiraj K, Jaccard H, Kretzschmar M, Helm L, Maecke HR. Novel DOTA-based prochelator for divalent peptide vectorization: synthesis of dimeric bombesin analogues for multimodality tumor imaging and therapy. Chem Commun (Camb). 2008;28:3248-3250.
23. Wester HJ, Kessler H. Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? J Nucl Med. 2005;46:1940-1945.